Purpose: To evaluate the effects of retinal angiography, using fluorescein and indocyanine green dyes, on optical coherence tomography (OCT) measurements. Methods: In total, 76 eyes from 76 consecutive patients were included. Macular cube 512 × 128 combination scanning and optic disc 200 × 200 scanning using spectral-domain (SD)-OCT were performed twice, before and after retinal angiography, with fluorescein or indocyanine green. Signal strength, regional retinal thickness of the 9 Early Treatment Diabetic Retinopathy Study subfields, total macular volume, and retinal nerve fiber layer thickness obtained before and after angiography were compared. Repeatability was also investigated. Results: Comparing the results of OCT measured before and after retinal angiography, there was no statistically significant difference in any parameter assessed. The interclass correlation values for each measurement were all >0.808 (range 0.808-0.999). Conclusion: Retinal angiography using fluorescein and indocyanine green dyes has no significant effect on OCT measurements.

Keywords:
Spectral-domain optical coherence tomography, Fluorescein angiography, Indocyanine green angiography
1.
Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flotte T, Gregory K, Puliafito CA, et al: Optical coherence tomography. Science 1991;254:1178-1181.
2.
Chen TC, Cense B, Pierce MC, Nassif N, Park BH, Yun SH, White BR, Bouma BE, Tearney GJ, de Boer JF: Spectral domain optical coherence tomography: ultra-high speed, ultra-high resolution ophthalmic imaging. Arch Ophthalmol 2005;123:1715-1720.
3.
Wojtkowski M, Srinivasan V, Fujimoto JG, Ko T, Schuman JS, Kowalczyk A, Duker JS: Three-dimensional retinal imaging with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology 2005;112:1734-1746.
4.
Novotny HR, Alvis DL: A method of photographing fluorescence in circulating blood in the human retina. Circulation 1961;24:82-86.
5.
Flower RW, Hochheimer BF: Clinical infrared absorption angiography of the choroid. Am J Ophthalmol 1972;73:458-459.
6.
Delori F, Ben-Sira I, Trempe C: Fluorescein angiography with an optimized filter combination. Am J Ophthalmol 1976;82:559-566.
7.
Baker KJ: Binding of sulfobromophthalein (BSP) sodium and indocyanine green (ICG) by plasma alpha-1 lipoproteins. Proc Soc Exp Biol Med 1966;122:957-963.
8.
Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-1806.
9.
Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;i:307-310.
10.
Johnson RN, McDonald HR: Fluorescein angiography: basic principles and interpretation; in Ryan SJ, Hinton DR, Schachat AP, Wilkinson CP (eds): Retina, ed 4. St Louis, CV Mosby, 2006, pp 873-916.
11.
Freddo TF: Shifting the paradigm of the blood-aqueous barrier. Exp Eye Res 2001;73:581-592.
12.
Van Best JA, Kappelhof JP, Laterveer L, Oosterhuis JA: Blood aqueous barrier permeability versus age by fluorophotometry. Curr Eye Res 1987;6:855-863.
13.
Moldow B, Sander B, Larsen M, Engler C, Li B, Rosenberg T, Lund-Andersen H: The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular oedema. Graefes Arch Clin Exp Ophthalmol 1998;236:881-889.
14.
Sander B, Best J, Johansen S, Kessel L, Moldow B: Fluorescein transport through the blood-aqueous and blood-retinal barriers in diabetic macular edema. Curr Eye Res 2003;27:247-252.
15.
Satoh K, Takaku Y, Ohtsuki K, Mizuno K: Effects of aging on fluorescein leakage in the iris and angle in normal subjects. Jpn J Ophthalmol 1999;43:166-170.
16.
Menke MN, Dabov S, Knecht P, Sturm V: Reproducibility of retinal thickness measurements in healthy subjects using spectralis optical coherence tomography. Am J Ophthalmol 2009;147:467-472.
17.
Wu H, de Boer JF, Chen TC: Reproducibility of retinal nerve fiber layer thickness measurements using spectral domain optical coherence tomography. J Glaucoma 2011;20:470-476.
18.
Sharma A, Oakley JD, Schiffman JC, Budenz DL, Anderson DR: Comparison of automated analysis of Cirrus HD OCT spectral-domain optical coherence tomography with stereo photographs of the optic disc. Ophthalmology 2011;118:1348-1357.
19.
Comyn O, Heng LZ, Ikeji F, Bibi K, Hykin PG, Bainbridge JW, Patel PJ: Repeatability of Spectralis OCT measurements of macular thickness and volume in diabetic macular edema. Invest Ophthalmol Vis Sci 2012;53:7754-7759.
20.
Samarawickrama C, Pai A, Huynh SC, Burlutsky G, Wong TY, Mitchell P: Influence of OCT signal strength on macular, optic nerve head, and retinal nerve fiber layer parameters. Invest Ophthalmol Vis Sci 2010;51:4471-4475.
21.
Wu Z, Vazeen M, Varma R, Chopra V, Walsh AC, LaBree LD, Sadda SR: Factors associated with variability in retinal nerve fiber layer thickness measurements obtained by optical coherence tomography. Ophthalmology 2007;114:1505-1512.
22.
Xu C, Ye J, Marks DL, Boppart SA: Near-infrared dyes as contrast-enhancing agents for spectroscopic optical coherence tomography. Opt Lett 2004;29:1647-1649.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.